Careers | Contact Us

About Us

Our Management

BioLineRx’s management team brings together seasoned executives with decades of experience in medicine, drug development, clinical studies, and financial and corporate development.  

Chief Executive Officer

Mr. Serlin was appointed Chief Executive Officer in October 2016. Prior to becoming our Chief Executive Officer, he served as our Chief Financial and Operating Officer from May 2009. From January 2008 to August 2008, Mr. Serlin served as the Chief Financial Officer and Chief Operating Officer of Kayote Networks Inc. From January 2006 to December 2007, he served as the Chief Financial Officer of Tescom Software Systems Testing Ltd. (TASE:TSCM), an IT services company publicly traded in both Tel Aviv and London. His background also includes senior positions at Chiaro Networks Ltd. and at Deloitte, where he was head of the SEC and U.S. Accounting Department at the National Office in Tel Aviv, as well as seven years at the SEC at its Washington, D.C., headquarters. Mr. Serlin currently serves as a director at Vascular Biogenics Ltd. (Nasdaq:VBLT). Mr. Serlin is a CPA and holds a B.Sc. in accounting from Yeshiva University and a Master’s degree in economics and public policy from The George Washington University.

Chief Financial Officer

Ms. Zeevi was appointed Chief Financial Officer in October 2016.  Ms. Zeevi joined BioLineRx in 2009 as its Director of Finance and Reporting and served as its Senior Director of Finance and Reporting from 2011 through 2016. Before joining BioLineRx, Ms. Zeevi was employed by Software Systems Testing Ltd., her last position there being Vice President Finance. Ms. Zeevi also served as a CPA at Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited. She holds a B.A. in business and accountancy from the College of Management Academic Studies in Israel.

Chief Business Officer

David Malek has served as our Chief Business Officer since October 2011. Prior to joining the Company, from 2006 to 2011 Mr. Malek served at Sanofi-Aventis in a number of management positions, including Marketing, Finance and Business Development. Most recently, he served as Director of Oncology - New Products and Business Development. Mr. Malek received an MBA from the Tuck Business School at Dartmouth University and a B.A. in statistics and political science from the University of Haifa.

Vice President Clinical and Medical Affairs

Abi Vainstein-Haras, M.D., was appointed Vice President Clinical and Medical Affairs in January 2017. From June 2014 to January 2017, Dr. Vainstein-Haras served as BioLineRx’s Senior Medical Director responsible for the clinical development of the Company’s clinical phase projects. Prior to joining BioLineRx, from 2012 to 2014, she served as the Director and Clinical Program Leader for COPAXONE® at Teva Pharmaceutical Industries Ltd., and from 2007 to 2012, she served in a number of medical positions in Innovative R&D at Teva. Dr. Vainstein-Haras holds an M.D. from University of Buenos Aires and is licensed to practice medicine in Israel.

Vice President Development

Ella Sorani, Ph.D., was appointed BioLineRx’s Vice President Development in January 2017. Before joining BioLineRx, from 2000 through 2016, Dr. Sorani served in a number of management positions in the global R&D division at Teva Pharmaceutical Industries Ltd. In her most recent position as Senior Director and Global Project Leader, Dr. Sorani led the global development of one of Teva’s leading innovative late stage compounds. Dr. Sorani holds a B.Sc. in chemistry and an M.Sc. and Ph.D. in pharmacology, all from Tel Aviv University.